Eight companies with immunotherapy approaches for brain tumors
2011 Review and Outlook for Biotechnology in 2012
January 25, 2012 By Leave a Comment
Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
Bear Market Advice and Perspectives
August 9, 2011 By Leave a Comment
Our management and strategy consulting firm was founded in November 2008, which was clearly a difficult period for the U.S. economy and a year that many investors would like to forget. The Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971. [...]
Similarities Between Two Immunotherapies in Cancer
March 30, 2011 By 1 Comment
Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Follow MD Becker Partners